Corvidia is a biotechnology company pioneering the next generation of cardiovascular therapies. Leveraging functional genomics, the company's founding team has decoded previously unrecognized genetic susceptibilities within general cardiovascular populations. Corvidia's pipeline programs precisely identify patients with unique sensitivity to specific biologic pathways, potentially allowing for the rapid development of therapies targeting those pathways.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/18/16 | $26,000,000 | Series A |
Apple Tree Partners Sofinnova Partners | undisclosed |
